Can Myasthenia Gravis Go Into Remission? Treatment Goals
At a Glance
While there is no definitive cure for myasthenia gravis (MG), achieving long-term remission is highly realistic. Many patients successfully taper their medications over time, reaching a state with no daily symptoms, either completely medication-free or on a low-dose maintenance therapy.
In this answer
3 sections
While there is no definitive “cure” for myasthenia gravis (MG), achieving long-term remission is a highly realistic goal for most patients. The endgame of MG treatment is not necessarily taking high doses of medication forever. Instead, the goal is to stabilize your immune system so that you experience little to no symptoms, allowing you to live a normal life. Many patients eventually taper down their medications significantly, and some are able to stop them entirely, though a portion will need to stay on a low-dose maintenance therapy to remain symptom-free [1].
Understanding the Goals of Treatment
Doctors use specific terms from the Myasthenia Gravis Foundation of America (MGFA) Post-Intervention Status to measure how well you are doing and to define the endgame of your treatment:
- Minimal Manifestation Status (MMS): This means you have no symptoms or functional limitations from MG that affect your daily life, even if a doctor can find mild weakness during a neurological exam [2][3]. You may or may not still be taking medications.
- Pharmacological Remission: This is when you have no symptoms and no signs of MG, but you are still taking some medication to maintain this symptom-free state [4][5].
- Complete Stable Remission (CSR): This is the highest level of remission. It means you have had no symptoms and no signs of MG for at least one year while taking absolutely no MG medications [6].
Reaching these goals can sometimes take months or even years of trial and error with different treatments, so patience is key [7].
Tapering Medications
Once you achieve a stable state like MMS or Pharmacological Remission, your doctor will likely discuss lowering your medication doses. Tapering is always done very slowly—often taking many months or even years, especially with steroids like prednisone—to prevent a relapse of your symptoms [8].
While a substantial number of patients eventually get off medications completely [6], it is also very common to require a small, maintenance dose of an immunosuppressant to keep the immune system in check [9]. For patients frustrated by steroid side effects, doctors frequently use steroid-sparing drugs (other immunosuppressants that do not contain steroids) to help maintain remission so that prednisone can eventually be stopped entirely [1]. Think of maintenance therapy like managing high blood pressure or asthma; the medication quietly keeps the condition under control.
Factors That Increase the Chances of Remission
Several factors can influence how likely you are to reach Complete Stable Remission or Minimal Manifestation Status:
- Thymectomy: Surgical removal of the thymus gland (thymectomy) has been shown to significantly increase the chances of achieving Complete Stable Remission and Pharmacological Remission [5]. This is especially true when surgery is performed early in the course of generalized MG, though it often remains a viable and beneficial option for patients who have had the disease for several years [2]. (Note: Surgery is universally required if a tumor, known as a thymoma, is discovered on the gland). The benefits of a thymectomy can last for many years, helping reduce the long-term need for medications [10][11].
- Milder Starting Symptoms: Having a lower severity score when you are first diagnosed, or having only ocular (eye) MG, are strong predictors that you will reach Minimal Manifestation Status [3].
- Targeted Therapies: Modern treatments are changing the landscape of MG care. For example, rituximab is highly effective for patients with the MuSK antibody type, helping over half of them achieve Minimal Manifestation Status on very little medication [6][4]. Other newer biologic therapies are also helping patients who did not respond to older drugs reach their remission goals, often serving as powerful alternatives to long-term steroids [12][13].
Common questions in this guide
Can myasthenia gravis go into remission?
What is Complete Stable Remission in myasthenia gravis?
Will I have to take myasthenia gravis medication forever?
How does a thymectomy affect myasthenia gravis remission?
What does Minimal Manifestation Status mean?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my antibody status and symptom history, how realistic is Complete Stable Remission for me?
- 2.What are the specific clinical milestones I need to hit before we can safely discuss tapering my current medications?
- 3.Am I a candidate for a thymectomy to help achieve remission, even though I was diagnosed a few years ago?
- 4.If my goal is to get off steroids completely, what are my options for 'steroid-sparing' maintenance therapies or newer biologics?
- 5.If we begin tapering my medications and my symptoms return, what is our immediate action plan to stabilize me?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Myasthenia gravis.
Gilhus NE, Tzartos S, Evoli A, et al.
Nature reviews. Disease primers 2019; (5(1)):30 doi:10.1038/s41572-019-0079-y.
PMID: 31048702 - 2
Thymectomy in ocular myasthenia gravis before generalization results in a higher remission rate.
Li F, Li Z, Chen Y, et al.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2020; (57(3)):478-487 doi:10.1093/ejcts/ezz275.
PMID: 31628812 - 3
Factors affecting minimal manifestation status induction in myasthenia gravis.
Li Y, Yang S, Dong X, et al.
Therapeutic advances in neurological disorders 2022; (15()):17562864221080520 doi:10.1177/17562864221080520.
PMID: 35371293 - 4
Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis.
Chayanopparat S, Banyatcharoen P, Jitprapaikulsan J, et al.
Scientific reports 2025; (15(1)):7219 doi:10.1038/s41598-025-90937-w.
PMID: 40021769 - 5
Clinical Profile and Outcome of Postthymectomy versus Non-Thymectomy Myasthenia Gravis Patients in the Philippine General Hospital: A 6-Year Retrospective Study.
De Roxas RC, Bagnas MA, Baldonado JJ, et al.
Frontiers in neurology 2016; (7()):96 doi:10.3389/fneur.2016.00096.
PMID: 27445963 - 6
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
Narayanaswami P, Sanders DB, Wolfe G, et al.
Neurology 2021; (96(3)):114-122 doi:10.1212/WNL.0000000000011124.
PMID: 33144515 - 7
Recommendations for the management of myasthenia gravis in Belgium.
De Bleecker JL, Remiche G, Alonso-Jiménez A, et al.
Acta neurologica Belgica 2024; (124(4)):1371-1383 doi:10.1007/s13760-024-02552-7.
PMID: 38649556 - 8
Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis.
Su S, Lei L, Fan Z, et al.
Frontiers in neurology 2022; (13()):816243 doi:10.3389/fneur.2022.816243.
PMID: 35185767 - 9
Longitudinal treatment patterns in myasthenia gravis: An analysis from the prospective Dutch-Belgian patient registry.
Remijn-Nelissen L, Tannemaat MR, Verschuuren JJ
Journal of neuromuscular diseases 2026; (13(3)):445-452 doi:10.1177/22143602251405924.
PMID: 41364382 - 10
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Wolfe GI, Kaminski HJ, Aban IB, et al.
The Lancet. Neurology 2019; (18(3)):259-268 doi:10.1016/S1474-4422(18)30392-2.
PMID: 30692052 - 11
Thymomatous myasthenia gravis: 10-year experience of a single center.
Chen J, Shang W, Chen Y, et al.
Acta neurologica Scandinavica 2021; (143(1)):96-102 doi:10.1111/ane.13332.
PMID: 32762063 - 12
Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.
Samara VC, Thottempudi N, Franke O, Tabaac BJ
American journal of therapeutics 2026; (33(1)):e46-e49 doi:10.1097/MJT.0000000000002052.
PMID: 41505161 - 13
Rozanolixizumab: A New Therapy in the Treatment of Myasthenia Gravis.
Hitt EM
The Annals of pharmacotherapy 2024; (58(11)):1140-1148 doi:10.1177/10600280241239048.
PMID: 38533739
This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist before modifying your myasthenia gravis medication or treatment plan.
Get notified when new evidence is published on Myasthenia gravis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.